New immunotherapy combo takes on advanced liver cancer

NCT ID NCT06737913

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if this mix shrinks tumors better than current options. About 76 adults with advanced liver cancer who haven't had prior treatment will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug), bevacizumab (a drug that blocks blood vessel growth), and FOLFOX chemotherapy (a combination of three chemo drugs)
What this could lead to: If this works, it could offer a new first-line treatment option for advanced liver cancer that has spread, potentially shrinking tumors and extending life.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 76 people, so results may not apply to everyone. The combination of drugs can cause serious side effects like immune reactions, bleeding, or liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Gansu Province Cancer Hospital
RECRUITING

Lanzhou, Gansu, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.